Beike Biotech published a theme article in the supplement “Nature Focus-Precision Medicine in China” of “Nature”

In 2016, the Chinese government officially included precision medicine in the “13th Five-Year Plan” economic plan, which has greatly promoted the development of domestic precision medicine research. With the advancement of medicine and biological sciences, regenerative medicine, which focuses on the repair of tissue and organ damage, and precision medicine, which focuses on changes in treatment methods, are becoming important components of emerging medical fields. Progress in basic research and clinical translation in the field of stem cells can provide a huge impetus for the development of these fields.

June 29, 2022, “Nature” official website nature The “Nature Focus – Precision Medicine in China” section of the spotlight supplement published online a theme article by the team of Professor Cai Cheguo, chief scientist of Beike Biotechnology: Stem cell advances drive better personalized medicine.

Stem cell advances drive better personalized medicine

——With the mission of promoting precision medicine (one of the leading stem cell banks in China)

The collection and cryopreservation of stem cells for future clinical treatments is at the heart of the stem cell industry. Since the establishment of Shenzhen Beike Biotechnology Co., Ltd. in 2005, the company has earned the reputation of “China’s leading stem cell repository” and established an excellent and experienced team of stem cell experts. Currently, the company’s goal in the storage business is to allow more families to enjoy advanced cell storage services.
Storing stem cells involves a series of strict steps, starting from the collection of samples in the hospital, from transportation to preparation, until the samples are stored in liquid nitrogen tanks. The entire process must be strictly controlled. Professor Cai Cheguo, the company’s chief scientist, said: “This complicated process requires the participation of a large number of professional and technical personnel and strict quality control.”
According to Professor Cai, “A significant advantage of Beike Biotech’s stem cell storage technology is the use of special freezing media, which can be stored or transported at room temperature. This eliminates the need for pre-cooling before cell storage, reduces turnaround time, and improves efficiency.”
“The company’s storage business process is extremely strict,” Professor Cai explained, “We have about 60 patents related to stem cell preparation and cryopreservation, and we strictly treat every stored stem cell sample through more than 580 standard operating procedures and about 740 quality control records. Now, we have a better understanding of stem cells, and are fully prepared to apply the knowledge and technology obtained in the laboratory to the development of stem cell drugs, and use it to inspire more impact on the real world.”

Professor Cai’s laboratory research team at Wuhan University focuses on the research of mammary gland organoids, which uses stem cell culture technology in vitro to obtain 3D-structured cultures that exhibit the gene expression characteristics and morphological structural characteristics of the mammary gland. When Dr. Hu Junyuan, founder of Shenzhen Beike Biotechnology Co., Ltd., sought to collaborate with Professor Cai, the two scientists proposed a collaboration idea,That is, the development of patient-derived organoid models (Patient Derived Organoid, PDO) as in vitro disease model systems.
Patients with malignant tumors often face difficulties in choosing treatment drugs and treatment plans during clinical treatment. Part of the reason for this phenomenon is that everyone has different responses to treatment, and doctors need to make adjustments while treating. Now, The team of scientists from Shenzhen Beike Biotechnology Co., Ltd. is developing an in vitro drug testing system based on the PDO model, which is expected to provide patients with personalized and precise treatment plans in the future.
“The technological development of PDO models is an example of Beike Biotech’s rich scientific and technological innovation pipeline. Some candidate disease PDO models will be released by the end of 2022.” Professor Cai added: “We improve human health through the construction of PDO models of multiple diseases and multiple tissues, as well as the accumulation of research discoveries and technical capabilities in stem cells. We welcome more like-minded partners to join this industry to jointly serve human health.”

Supplementary series of reports: https://www.nature.com/collections/dbafabjahe

Beike Biological Special Report: https://www.nature.com/articles/d42473-022-00201-2

“nature spotlight” special report on the public account:：https://mp.weixin.qq.com/s/WCrP-zLwir4xAGL2IEOaRA